The immunotherapy for malignant glioma faces unique difficult, due to some anatomical and immunological characteristics including the existence of blood brain barrier, the absence of lymphatic tissues and dendritic cells (DCs) in the central nervous system (CNS) parenchyma, and the presence of an immunosuppressive microenvironment. Therefore, immunotherapeutic approaches will not be beneficial unless the compromised immune status in malignant glioma patients is overcome. DCbased immunotherapy, vaccinating cancer patients with DCs pulsed with various tumor antigens, is one of the most promising immunotherapeutic approaches for treatment of malignant glioma because it seems able to overcome, at least partially, the immunosuppressive state associated with primary malignancies. The preparation of DCs, choice of antigen, and route and schedule of administration are improving and optimizing with rapid development of molecular biology and gene engineering technology. DC vaccination in humans, after a number of pre-clinical models and clinical trials, would increase the clinical benefits for malignant glioma immunotherapy.
Despite malignant gliomas are located in the central nervous system (CNS), a site which is described as "immune privileged", numerous animal model experiments and clinical trials have demonstrated that they can be effectively targeted by activated immune system following various immunotherapeutic strategies. Immunotherapy is designed to aid immune system to recognize and destroy tumor cells in order to eliminate the tumor burden. One of the most promising immunotherapeutic approaches for treatment of malignant glioma is vaccination with dendritic cells (DCs) pulsed with tumor antigens. This review will highlight recent advances of DC-based immunotherapy for malignant glioma.
Challenges in malignant glioma immunotherapy
Both the anatomical characteristics of CNS and the immune milieu of malignant glioma create a pessimistic scenario that effective immunotherapy faces many challenges. Firstly, the brain parenchyma is not only protected by the blood brain barrier (BBB), but also lack of lymphatic tissues and DCs. So the immunoreaction of brain parenchyma is different from that outside the central nervous system, in which various antigens can be phagocytosed and transported to peripheral lymphoid organs to elicit an adaptive immune response [1] [2] [3] [4] [5] . Furthermore, there is a complete absence of lymphatic structures, and noticeable absence of immune cells in the brain parenchyma of higher vertebrates. Neutrophils, the largest population of circulating leukocytes involved in innate immunity, are rarely detected in either cerebrospinal fluid (CSF) or brain parenchyma [6, 7] . DCs have not been detected in the normal brain [6, 8] although they are observed in the meninges and choroids plexi [2, 3, 9, 10] . These suggest that the complete monitoring for foreign agents is deficient and which in turn limits the response of immune system to antigens in the CNS. Secondly, the presence of malignant glioma adds another set of challenges by creating an immunosuppressive environment in which tumor can evade monitoring and is favorable to their continued growth. Within the glioma mass, through the secretion of interleukin-10 (IL-10), prostaglandin E2 (PGE2) and tumor growth factor (TGF-) [11] , T-cell development, proliferation, activation, and cytotoxic T-cell are inhibited, major histocompatibility complex (MHC) expression is down regulated, and antigen presentation to CD4 + T cells decreased [12] . These evidences indicate that the environment created by malignant glioma cells actively limits the ability of immune system to eliminate tumor, so immunotherapy for malignant glioma faces unique difficult.
A better understanding of DC biology for malignant glioma immunotherapy
As described above, immunotherapeutic approaches would not benefit unless the compromised immune status in malignant glioma patients is overcome. Cellular immunotherapies, such as adoptive transfer of lymphokine-activated killer cells (LAK), tumor-infiltrating lymphocytes (TIL), and tumor-sensitized cytotoxic T lymphocyte (CTL), as well as vaccination with irradiated tumor cells have been performed, but there were limited effects in glioma patients [13] . Tumor-antigen pulsed DCs, which are used as vaccines in vivo, offer the unique feature of presenting tumor specific peptides in the context of an efficient antigen processing and presenting machinery and a multitude of costimulatory molecules, thus stimulating immune effector cells in a very potent way.
There are usually two pathways to activate T cells. One is direct way, by which tumor antigen is directly presented to T cells and subsequently activates the antigen-specific T cell. Another is indirect pathway, utilizing specialized potent antigen presenting cells (APCs) to present antigen and activate T cells. DCs are the most potent APCs known to date. Upon the stimulation of inflammatory mediators and pathogens, immature DC resided in the peripheral tissues efficiently uptake and process antigens, migrate to the T cell areas of lymphoid organs and mature. Mature DCs lose their antigen-capturing capacity and present processed endogenous and exogenous antigens to naive T cells in a human leucocyte antigen (HLA)-restricted manner. CTL are thought to be the main effector cells in tumor rejection. DCs' infiltration into tumors has been associated with prolonged survival and reduced metastasizing capacity in cancer patients [14] . DC-based immunotherapy refers to vaccinating cancer patients with DCs pulsed with various tumor antigens.
Theoretically, co-injection of DCs and co-stimulatory molecules or DC growth factors will not only stimulate various effector immune cells, but also improve antigen presentation to DCs. Accumulative evidences demonstrate that immunotherapy with DC seems able to overcome, at least partially, the immunosuppressive state associated with primary malignancies. DC therapy proved to be safe in both animal models and clinical trials. No serious side effects and no evidence of autoimmune toxicity were observed until now. So DC-based immunotherapy for various malignancies is now gaining increasing attentions.
Dendritic cell-based immunotherapy for malignant glioma
There are various successful reports describing the efficacy of DC-based vaccination for malignant glioma both in extracranial experimental neoplastic models and clincal trials. Liau and his colleagues [15] described the optimistic use of tumor-peptide pulsed DC vaccination for treatment of established intracranial gliomas in rats. Yu et al. [16] have successfully performed a DC vaccine treatment in a phase I clinical trial involving patients with malignant glioma. DCs from patients' peripheral blood mononuclear cells (PBMCs) were pulsed ex vivo with autologous tumor cell surface peptides which were isolated by acid-elution. Nine patients (two with grade III astrocytoma, seven with glioblastoma) received DC vaccine following surgical resection and external beam radiotherapy. Result showed that the patients in the study group had a longer survival time than the age and gender matched controls who had undergone the surgical resection and external beam radiotherapy but without DC immunization. This result indicated that DC-based immunotherapy for malignant gioma patients was safe and effective, thus encouraged the expansion of this study into phase II and III clinical trials. Now key problems in the study of DC vaccination for malignant gioma are as follows.
Source and maturation of DCs
In general, DCs are largescale isolated, expanded and induced maturation in vivo. Proliferating CD34 + progenitor cells and non-proliferating CD14 + monocytic precursors from peripheral blood (PBMC) are the main souse of immature DCs [17] [18] [19] [20] [21] . Furthermore, spleengenerated DCs are also included in DC-precursors preparation [22] . Differences in their T cell priming capacity seemed to be mainly due to varying culture conditions [23] . Despite DCs from different origins can stimulate antitumor immune responses, the choice of the optimal precursor cells for generation of clinically administered DC vaccines does need to be further examined. Accumulative evidences demonstrate that cultured mature DCs are superior to immature DCs in eliciting both protective immunity and CTL responses against established tumors in vivo [24] . Thus some cytokines and chemokines such as GM-CSF, IL-4, IL-13, CD40L, TNF-and IL-2 should be co-cultured to promote the differentiation and maturation of DCs [25, 26] . Recently, it has been reported [27] that
DCs were expanded 20-fold in vivo by using Fems-like tyrosine 3 ligand (Flt-3) for treatment of cancer patients.
Choice of Antigen
The most important point in DCbased immunotherapy research is how to pulse DCs with appropriate peptide or antigen and then boost the tumor-specific CTL responses. A multitude of antigen-loading strategies have adopted effectively up to now, including cytokines, tumorassociated antigens, tumor cell lysate [17, 20, 28] , tumor-derived mRNA [18] , intact tumor cells [19, 22] , apoptotic body, and so on. As critical participants in the processes such as proliferation, differentiation, and antigen presentation of DCs, some cytokines combined with DCs could improve the vaccinal efficacy in theory. Transgenes, such as immunostimulatory cytokines (e.g. IL-12, IL-15, IL-18, GM-CSF) and costimulatory molecules (e.g. B7-1, ICAM-1), have been delivered by viral and non-viral vectors into DCs, and substantially improve the priming of CTL and CD4 + T helper cells [29, 30] . Specific recognition of tumor cells by infiltrating CTL is mediated by MHC-restricted presentation of antigens by glioma cells. A patient who was immunized with DCs pulsed with allogeneic MHC class I-matched glioblastoma peptides had shown a limited immunological response [21] . In malignant gliomas, only few tumor associated antigens representing targets for CTL were described, such as MAGE-1, MAGE-3 and SART3 [31, 32] . After being delivered into DCs by viral and non-viral vectors, transgenes tumor-associated antigens (e.g. MART-1, MAGE-3) produced by genetic engineering means showed substantial enhancement in their immunostimulatory capacity [29, 30] .
In fact, use of DCs loaded with a panel of tumor-associated antigens (such as tumor cell lysate or a mixture of peptides eluted from tumor cell membranes) seems to be a more promising therapy than use of DCs pulsed with defined tumor peptides. Liu et al. [33] showed the efficiency of DCs in treating intracerebral glioma in their rat C6 glioma model. From the next day after intracranial implantation of C6 cells ( 1×10 5 ), SD rats received three-weekly intratumoral injections of bonemarrow generated DCs which were pulsed ex vivo with acideluted antigens from C6 glioma cells. Results indicated that tumor group had many more necrotic cells than control group (P < 0.01), and DCs pulsed with the acid-eluted piptides derived from autologous tumors could promote tumor necrosis. An in vitro research also showed that immunization with DCs pulsed with allogeneic glioma-association antigen by freezemelt method could produce a significant immunological response [34] .
Transfection of tumor-derived cDNA or mRNA into DC via gene engineering technology is also one of the most promising approaches to pulse DC vaccines. Yamanaka R and his colleagues [18] utilized genetically modified DCs which were pulsed with Semilili Forest Virus (SFV)-mediated complementary DNA to enhance the antitumor immune response. In their model, the glioma RNA and the glioma lysate induced equal CTL response in DC-vaccinated mice, but the SFVmediated glioma cDNA had a stronger stimulatory capacity and resulted in cures of glioma-bearing animals. Moreover, cDNA can be easily obtained and amplified by RT-PCR, which make DC therapy overcome the dilemma that large amounts of tumor tissue are required for preparation of tumor lysate, tumor mRNA, and acid-eluted membrane peptides, while only small quantity of tumor tissue is available. Recently, hybrid cells produced by fusions of tumor and autologous DCs have demonstrated remarkable efficacy in stimulating the antitumor immune response of extra-cranial neoplasms in both preclinical and clinical studies. Akasaki et al. [19] studied the antitumor immunity conferred by fusions of dendritic cells and glioma cells in a mouse brain tumor model. Administration of fusion cells (FCs) alone had limited effects on survival rate of the mice bearing brain tumors; which was remarkably prolonged, however, by combined administration of FCs and recombinant interleukin-12 (rIL-12). Coadministration of FCs and rIL-12 also improved the CTL activity against glioma cells compared with only administration of FCs or rIL-12. These data support the therapeutic effect of combining FC-based vaccine therapy and rIL-12 administration. Kikuchi T and his colleagues investigated the safety and clinical response to the immunotherapy using fusion of dendritic and glioma cells in a clinical trial involving eight malignant glioma patients [35] . DCs were generated from peripheral blood and cultured autologous glioma cells were established from surgical specimens in each case. The fusion cells of dendritic and glioma cells were prepared with polyethylene glycol. The fusion efficiency ranged from 9.2% to 35.3% (mean, 21.9%). All patients received the immunization of FCs every three weeks, totally 3 to 7 times. FCs were injected intradermally close to a cervical lymph node. The percentage of CD16-and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. There were two partial responses and no serious adverse effects. Although the results of the phase I clinical trial of fusion cells indicated that this treatment induced immune responses safely, a statistically significant treatment-associated response rate, due to limited sample population, still unable to be established. Thus further evaluation of the role of adjuvant cytokines is necessary.
Route and Schedule of Administration
Efficient T cell priming in vivo requires migration of DCs to the T cell areas of lymphoid organs. So the route and schedule of vaccine administration seems to be of critical importance. Up to now, various possible administration routes including intravenous injection (i.v.), intradermal injection (i.d.), subcutaneous injection (s.c.), intraperitoneal injection (i.p.), and intranodal injection (i.n.) were used to augment the tumorspecific immunity of DC vaccinations. Increasing data suggests that tumor antigen-specific T cell responses could be elicited in all cancer patients who treated by DC vaccinations either via a single route or via a combination of i.v., s.c., i.d. and i.n. administration [36] . Ali S et al. [37] developed a novel approach, intracranial injection, attempting to increase DC's infiltration into glioma. Results demonstrated that the infiltration of macrophages and CD8 + T-cells into tumor increased largely and the survival rate in rat model improved significantly. Although the optimal schedule for DC immunotherapy is still under investigation, a consensus that DC vaccines should be administered repeatedly has reached, as booster immunizations was shown to increase antigen-specific T cell responses strongly [38] . Akasaki et al. [19] showed that tumor-specific CTL-responses increased significantly if glioma-bearing animals received two times of DC injections instead of only one time (P < 0.001). Prolonged survival rates and even cure of tumor-bearing animals were achieved by either s.c., i.p. (animal studies) or i.d. (human trials) injection of DCs, implying that all the three routes enable DCs to get in close with effector T cells, e.g. migrating to draining lymph nodes [38] .
Conclusion
As an adjuvant treatment, the use of dendritic-cell based immunotherapy now is still limited in the situations when open resection of tumor is inaccessible. With the rapid development of molecular biology and gene engineering technology, mechanisms of DCs in the setting of gliomainduced immunosuppression will be better understood. Furthermore, the preparation, immunotherapeutic efficiency, and constancy of DC vaccination will be optimized and improved, and elimination of major side-effects for safer clinical application can be expected.
